Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A fluvoxamine-caffeine interaction study

U Jeppesen1, S Loft, H E Poulsen

  • 1Department of Clinical Pharmacology, Odense University, Denmark.

Pharmacogenetics
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Birth Cohort Studies of Long-Term Exposure to Ambient Air Pollution in Early Life and Development of Asthma in Children and Adolescents from Denmark.

Research report (Health Effects Institute)·2024
Same author

Long-Term Exposure to AIR Pollution and COVID-19 Mortality and Morbidity in DENmark: Who Is Most Susceptible? (AIRCODEN).

Research report (Health Effects Institute)·2024
Same author

Ultrafine particle exposure for bicycle commutes in rush and non-rush hour traffic: A repeated measures study in Copenhagen, Denmark.

Environmental pollution (Barking, Essex : 1987)·2021
Same author

Exposure to ultrafine particles while walking or bicycling during COVID-19 closures: A repeated measures study in Copenhagen, Denmark.

The Science of the total environment·2021
Same author

Household dampness and microbial exposure related to allergy and respiratory health in Danish adults.

European clinical respiratory journal·2020
Same author

A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder.

Acta psychiatrica Scandinavica·2018
Same journal

No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility.

Pharmacogenetics·2004
Same journal

Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.

Pharmacogenetics·2004
Same journal

Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells.

Pharmacogenetics·2004
Same journal

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.

Pharmacogenetics·2004
Same journal

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

Pharmacogenetics·2004
Same journal

The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse.

Pharmacogenetics·2004
See all related articles

Fluvoxamine, a selective serotonin reuptake inhibitor, significantly inhibits CYP1A2, the enzyme that metabolizes caffeine. This drug interaction can increase caffeine levels, potentially causing intoxication.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Clinical Pharmacology

Background:

  • The liver enzyme CYP1A2 is crucial for metabolizing caffeine.
  • Selective serotonin reuptuptake inhibitors (SSRIs) like fluvoxamine are known potent inhibitors of CYP1A2.
  • Understanding drug-drug interactions is vital for patient safety.

Purpose of the Study:

  • To investigate the pharmacokinetic interaction between fluvoxamine and caffeine.
  • To quantify the effect of fluvoxamine on caffeine's metabolic pathways.
  • To confirm CYP1A2's role in caffeine biotransformation.

Main Methods:

  • A randomized, in vivo, cross-over study involving eight healthy volunteers.
  • Administration of caffeine alone, followed by caffeine during a course of fluvoxamine treatment.

Related Experiment Videos

  • Analysis of caffeine and its metabolites in plasma and urine using High-Performance Liquid Chromatography (HPLC).

    • Main Results:

    • Fluvoxamine significantly reduced total caffeine clearance (107 to 21 ml/min) and increased half-life (5 to 31 h).
    • Metabolic pathways N3-, N1-, and N7-demethylation of caffeine were significantly decreased during fluvoxamine treatment.
    • These findings confirm CYP1A2 as the primary enzyme for caffeine metabolism.

    Conclusions:

    • Fluvoxamine is a potent inhibitor of CYP1A2, significantly impacting caffeine metabolism.
    • Concurrent intake of caffeine and fluvoxamine may lead to caffeine intoxication due to reduced clearance.
    • Fluvoxamine serves as a useful probe for assessing CYP1A2 activity in drug metabolism studies.